U.S. markets close in 1 hour 58 minutes

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.66-0.03 (-0.35%)
As of 1:40PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close8.69
Open8.60
Bid8.66 x 3000
Ask8.75 x 3000
Day's Range8.51 - 8.75
52 Week Range6.79 - 13.70
Volume15,049
Avg. Volume58,628
Market Cap36.875M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
169% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
    Benzinga

    The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 14) * Acceleron Pharma Inc (NASDAQ: XLRN) (announced orphan drug designation for sotatercept in pulmonary arterial hypertension) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * Affimed NV (NASDAQ: AFMD) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) - announced a deal to be bought by AstraZeneca plc (NASDAQ: AZN) for $39 billion * Agios Pharmaceuticals Inc (NASDAQ: AGIO) * Alkermes Plc (NASDAQ: ALKS) * Amicus Therapeutics, Inc. (NASDAQ: FOLD) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * argenx SE - ADR (NASDAQ: ARGX) * Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) * Arvinas Inc (NASDAQ: ARVN) (announced positive results for early stage breast cancer studies) * Ascendis Pharma A/S (NASDAQ: ASND) * Athira Pharma Inc (NASDAQ: ATHA) * Beam Therapeutics Inc (NASDAQ: BEAM) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BioCardia Inc (NASDAQ: BCDA) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) * BioLife Solutions Inc (NASDAQ: BLFS) * BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX) * Blueprint Medicines Corp (NASDAQ: BPMC) * BridgeBio Pharma Inc (NASDAQ: BBIO) * CareDx Inc (NASDAQ: CDNA) * Castle Biosciences Inc (NASDAQ: CSTL) * Cellectis SA (NASDAQ: CLLS) * Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) * Corcept Therapeutics Incorporated (NASDAQ: CORT) * Curis, Inc. (NASDAQ: CRIS) * Denali Therapeutics Inc (NASDAQ: DNLI) * Editas Medicine Inc (NASDAQ: EDIT) * Eidos Therapeutics Inc (NASDAQ: EIDX) -reacted to reports of a rival bid from GlaxoSmithKline plc (NYSE: GSK) * Evelo Biosciences Inc (NASDAQ: EVLO) * Fate Therapeutics Inc (NASDAQ: FATE) * Foghorn Therapeutics Inc. (NASDAQ: FHTX) * Frequency Therapeutics Inc (NASDAQ: FREQ) * Globus Medical Inc (NYSE: GMED) * ImmunoGen, Inc. (NASDAQ: IMGN) * Inhibrx Inc (NASDAQ: INBX) * Insmed Incorporated (NASDAQ: INSM) * Intellia Therapeutics Inc (NASDAQ: NTLA) * InVitae Corp (NYSE: NVTA) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) (announced the appointment of Jean-Marc Bellemin as CFO) * Kymera Therapeutics Inc (NASDAQ: KYMR) * MannKind Corporation (NASDAQ: MNKD) * Mirati Therapeutics Inc (NASDAQ: MRTX) * Natera Inc (NASDAQ: NTRA) * NeoGenomics, Inc. (NASDAQ: NEO) * Neuronetics Inc (NASDAQ: STIM) * NGM Biopharmaceuticals Inc (NASDAQ: NGM) * Novocure Ltd (NASDAQ: NVCR) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Otonomy Inc (NASDAQ: OTIC) * Pacific Biosciences of California Inc (NASDAQ: PACB) * PRA Health Sciences Inc (NASDAQ: PRAH) * Praxis Precision Medicines Inc (NASDAQ: PRAX) * Precigen Inc (NASDAQ: PGEN) * Prelude Therapeutics Inc (NASDAQ: PRLD) * Provention Bio Inc (NASDAQ: PRVB) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * Pulse Biosciences Inc (NASDAQ: PLSE) * Sarepta Therapeutics Inc (NASDAQ: SRPT) (announced management changes) * Spero Therapeutics Inc (NASDAQ: SPRO) * Stoke Therapeutics Inc (NASDAQ: STOK) * Surface Oncology Inc (NASDAQ: SURF) * Tarsus Pharmaceuticals Inc (NASDAQ: TARS) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) (reacted to data from Phase 1/2 study of TC-210 in mesothelin-expressing solid tumors) * TG Therapeutics Inc common stock (NASDAQ: TGTX) * Travere Therapeutics Inc (NASDAQ: TVTX) * Turning Point Therapeutics Inc (NASDAQ: TPTX) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * United Therapeutics Corporation (NASDAQ: UTHR) * Veru Inc (NASDAQ: VERU) (announced positive midstage breast cancer study) * Xencor Inc (NASDAQ: XNCR) * XOMA Corp (NASDAQ: XOMA) * 'X T L Biopharmaceuticals Ltd (NASDAQ: XTLB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Dec. 14) * Avita Therapeutics Inc (NASDAQ: RCEL) * InMed Pharmaceuticals Inc (NASDAQ: INM) * Nanobiotix S.A. (NASDAQ: NBTX)Stocks In Focus Mediwound Announces Distribution Agreement For Severe Burn Treatment In UAE Mediwound Ltd (NASDAQ: MDWD) announced the signing of a distribution agreement with UAE's Ghassan Aboud Group, giving the latter an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns.Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year, the company said.The stock was up 7.69% at $3.92 premarket Tuesday.Kezar Life Sciences, Legend Biotech, MediciNova to Join Nasdaq Biotech Index Kezar Life Sciences Inc (NASDAQ: KZR), Legend Biotech Corp (NASDAQ: LEGN) and MediciNova, Inc. (NASDAQ: MNOV) announced separately that their shares will be added to the Nasdaq Biotech Index prior to the open of the market on Dec. 21.Kezar shares were up 13.92% premarket at $6.30, while Legend Biotech rose 2.47% to $30.74.Ziopharm Announces Departure of CFO ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) announced that CFO Satyavrat Shukla will step down from the role effective Dec. 31 to pursue another opportunity. The company said it has initiated a search for a new CFOIn after-hours trading, the stock declined 0.97% to $3.06.Related Link: The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenicsOpiant Gets Additional BARDA Funding For Development of Opioid Overdose Drug Opiant Pharmaceuticals Inc (NASDAQ: OPNT) said the BARDA has announced an additional commitment of up to $3.5 million to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1 million, Opiant said. The company said it remains on track to file an NDA for the investigational asset by the end of 2021.The stock jumped 22.26% to $10.16 premarket. Mesoblast Reports Mixed Results For Late-Stage Study Of Stem Cell Therapy In Advanced Chronic Heart Failure Mesoblast limited (NASDAQ: MESO) announced mixed top-line results from the DREAM-HF Phase 3 study of its allogeneic cell therapy rexlemestrocel-L in 537 patients with advanced chronic heart failure.Over a mean 30 months of follow-up, patients with advanced chronic heart failure who received a single endomyocardial treatment with rexlemestrocel-L on top of maximal therapies had 60% reduction in incidence of heart attacks or strokes and 60% reduction in death from cardiac causes when treated at an earlier stage in the progressive disease process, the company said.Yet there was no reduction in recurrent non-fatal decompensated heart failure events, which was the trial's primary endpoint, the company said. The stock was down 14.15% premarket at $14.50. Neovasc Found In Violation of Nasdaq Listing Standards Neovasc Inc (NASDAQ: NVCN) said it has received written notification from the Nasdaq that the company is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. The company has been given until June 14, 2021 to regain compliance.Burning Rock In-Licenses OncoCyte's Lung Cancer Test In China Burning Rock Biotech Ltd (NASDAQ: BNR) announced a licensing agreement with OncoCyte Corp (NYSE: OCX) to bring the latter's DetermaRx, a risk stratification test for early stage lung cancer patients, to China.In premarket trading Tuesday, Burning Rock shares were slipping 0.41% to $24.55, while OncoCyte was advancing 19.34% to $2.53.Offerings Ocular Therapeutix Inc (NASDAQ: OCUL) said it has commenced an underwritten public offering of $75 million of its common stock. All of the shares in the offering are to be sold by the company.The stock was down 3.67% at $21.50 premarket Tuesday.Mirum Pharmaceuticals Inc (NASDAQ: MIRM) priced its previously announced underwritten public offering of 3.75 million shares of its common stock at $20 per share for raising gross proceeds of $75 million.The stock fell 15.75% to $20.22 in premarket trading. Castle Biosciences Inc (NASDAQ: CSTL) said it has commenced a proposed underwritten public offering of $125 million of its common stock.In after-hours trading, the stock moved down 1.08% to $61.25.Cellectis announced the launch, subject to market conditions, of an underwritten public offering of $100 million of its ADSs, each representing one ordinary share of Cellectis.The stock was down 8.81% premarket at $28.46.BioCardia said it has entered into definitive agreements with investors for the sale of 1.89 million shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market. The offering is expected to close Dec. 16.In premarket trading Tuesday, BioCardia shares were retreating 4.46% to $4.28.On The Radar Adcom Review FDA's Cardiovascular and Renal Drugs Advisory Committee is scheduled to discuss Novartis AG's (NYSE: NVS) supplemental new drug application for Entresto (sacubitril and valsartan) tablets, for the proposed indication of heart failure with preserved ejection fraction.Clinical Readouts Gossamer Bio Inc (NASDAQ: GOSS) will release initial results from the ongoing two-week Phase 1b clinical trial of GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension. The release is scheduled for 11 a.m.Related Link: Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * 5 Biopharma Stocks Making Big Moves Monday * The Week Ahead In Biotech: 2 IPOs Plus FDA Decisions On Moderna's COVID Vaccine And Drugs From Amgen, MacroGenics(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
    GlobeNewswire

    Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

    SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene, for opioid overdose. The contract modification increases the total potential value of the BARDA contract to $8.1 million. “We thank BARDA for their ongoing support of OPNT003, nasal nalmefene,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “We believe OPNT003, nasal nalmefene, has the potential to be a best-in-class rescue agent for preventing opioid overdose deaths, particularly from synthetic opioids like fentanyl. We remain on track to file a New Drug Application with the U.S. Food and Drug Administration by the end of 2021.”An earlier award from BARDA for up to $4.6 million, combined with a $7.4 million grant Opiant received from the National Institute on Drug Abuse (“NIDA”), also supports the clinical development and U.S. regulatory submission of OPNT003. The additional BARDA support will fund both a planned pharmacodynamic study in healthy volunteers and development work associated with the use of Aptar Pharma’s Unit Dose System.Opioid overdose is a significant public health crisis that has been exacerbated by the increased availability and abuse of synthetic opioids, such as fentanyl. Fentanyl is 50-fold more potent than heroin, far easier and less expensive to produce, and has a significantly longer half-life. Fentanyl and related synthetic opioids were linked to more than 75% of the nearly 51,000 opioid overdose deaths in 2019 in the U.S. The contract with BARDA allows for development of OPNT003 as a medical countermeasure in a chemical attack using synthetic opioids.This project has been supported in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201800029C.About OPNT003 OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. OPNT003 is also being considered as an antidote in a civilian mass casualty event. The development of OPNT003 is supported by grants from the NIH and BARDA. Opiant intends to pursue a 505(b)(2) regulatory pathway for OPNT003.About Opiant Pharmaceuticals, Inc.  Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.Forward-Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled "Risk Factors."  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.For Media and Investor Inquiries: Ben Atkins, Opiant (310) 598-5410 batkins@opiant.com

  • Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
    GlobeNewswire

    Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing

    SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security Agreement (“Agreement”) with a syndicate of Pontifax Medison Finance (“Pontifax”), a healthcare-dedicated venture and debt fund, and Kreos Capital, Europe’s leading growth debt firm. Opiant plans to use the proceeds to fund the potential future commercialization of OPNT003, nasal nalmefene, an investigational treatment for opioid overdose, which the company aims to file for approval by the U.S. Food and Drug Administration (“FDA”) at the end of 2021.Under the Agreement, Opiant will be able to draw up to $50 million in three tranches. The first tranche of $20 million was funded at closing on December 10, 2020; a second tranche of $10 million will be available upon submission of a New Drug Application to the FDA; and a third tranche of $20 million will be funded upon FDA approval of an opioid overdose product. Each tranche will mature over 5 years and have an interest-only period of 30 months at an average rate of 8.75%. Subject to certain limitations, Pontifax and Kreos can elect to convert up to half of their outstanding loan into shares of Opiant’s common stock at a conversion price of $19.64 per share. Further information with respect to the Agreement is set forth in a Form 8-K filed by Opiant with the Securities and Exchange Commission on December 10, 2020.“This financing, together with the $31.1 million of cash on our balance sheet, provides Opiant with the financial flexibility to potentially launch OPNT003 without the need for additional financing,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant. “This Agreement, along with the recent appointment of Craig Collard, a seasoned biopharma leader, as Chairman of our Board of Directors, positions us well to deliver on our mission to develop and bring to market best-in-class medicines for addiction and overdose.”“We look forward to partnering with a company as innovative as Opiant,” said Momi Karako, partner at Pontifax. “The Company is making excellent progress advancing OPNT003, and it is a privilege to be working with a team whose potential to make a difference is so great.”“Kreos is pleased to provide this financing to Opiant,” said Aris Constantinides, partner at Kreos Capital. “This is an underserved market and Opiant, a company advancing the field of addiction, could play an important role in addressing the growing opioid addiction crisis.”Jefferies acted as the exclusive financial adviser to Opiant and Wilson, Sonsini, Goodrich & Rosati served as legal advisor. Kramer Levin acted as legal advisor to Pontifax and Kreos Capital.About Opiant Pharmaceuticals, Inc.  Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.For more information visit: www.opiant.com.Forward-Looking Statements This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 4, 2020, including under the caption titled "Risk Factors."  These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.For Media and Investor Inquiries: Ben Atkins, Opiant (310) 598-5410 batkins@opiant.com